Important OptumRx updates to support providers, clinical staff and patients through COVID-19.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 14, 2020 - AstraZeneca announced that Bydureon (exenatide) Pen will be discontinued as of March 2021 due to business reasons.
Download PDF
Return to publications
